We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

GSK Drug Single Dose Escalation And Their Effect On Resting Motor Threshold In Healthy Volunteers

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00488566
First Posted: June 20, 2007
Last Update Posted: October 26, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Biogen
  Purpose
This is a First Time in Human Study to assess the safety, tolerability, pharmacokinetics and resting motor threshold (rMT) of single doses of GSK drug in healthy volunteers.This will be a 2 part and 2 centre study.Part 1 will be a double-blind, randomized, placebo-controlled, single oral dose, dose-rising, cross-over study in healthy male and female (of non-child bearing potential) volunteers.Subjects will be randomized into cohorts of 10 subjects and cohorts will be recruited until the pre-defined safety or PK stopping limits are reached.Each subject will receive placebo and no more than 4 ascending doses of GSK drug in a randomized sequence on 5 separate study occasions.Each dosing session will take place over 2 days and there will be at least one subject on placebo on each day. There will be only one subject on any new active dose during the first day.Part 2 will be a randomised, double-blind, double-dummy, placebo-controlled, cross-over study to investigate the effect of single doses of GSK drug and lamotrigine on resting motor threshold in healthy male subjects. Subjects will attend the unit a maximum of 4 separate occasions.During each session subjects will receive up to 4 TMS measurements and single doses of either GSK drug, lamotrigine or placebo, in a randomised manner.Up to two doses of GSK drug will be investigated.

Condition Intervention Phase
Bipolar Disorder Drug: GSK drug Other: Placebo Other: Lamictal Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Double Blind, Randomised, Placebo Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Doses of GSK Drug and the Effect of Single Doses of GSK Drug or Lamotrigine on Resting Motor Threshold in Healthy Volunteers

Resource links provided by NLM:


Further study details as provided by Biogen:

Primary Outcome Measures:
  • Part1:AEs for the duration of the study; [ Time Frame: duration of the study ]
  • ECG,vitals and MAO activity predose and upto 48h post dose; [ Time Frame: predose and upto 48h post dose ]
  • clinical labs predose and upto 24h post dose. [ Time Frame: predose and upto 24h post dose ]
  • PK parameters up to 48h post dose. [ Time Frame: up to 48h post dose ]
  • Part2:Difference in rMT between pre-and post-dose and relationship with PK. [ Time Frame: between pre-and post-dose and relationship with PK ]

Secondary Outcome Measures:
  • Part1:Bond-Lader and body sway predose and upto 24h postdose. [ Time Frame: predose and upto 24h postdose ]
  • Part2:AEs for the duration of the study;. [ Time Frame: duration of the study ]
  • ECG,vitals and MAO activity predose and upto 48h postdose; [ Time Frame: predose and upto 48h postdose ]
  • clinical labs predose and upto 24h postdose [ Time Frame: predose and upto 24h postdose ]

Enrollment: 50
Actual Study Start Date: May 31, 2007
Study Completion Date: May 31, 2008
Primary Completion Date: May 31, 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Part 1
Single dose escalation
Drug: GSK drug
GSK drug
Other Name: BIIB074 and CNV1014802
Other: Placebo
Placebo
Part 2
Pharmacodynamic assessment
Drug: GSK drug
GSK drug
Other Name: BIIB074 and CNV1014802
Other: Placebo
Placebo
Other: Lamictal
Positive control

Detailed Description:
This study, previously posted by GlaxoSmithKline (GSK), was transitioned to Convergence Pharmaceuticals, Ltd., which spun off from GSK. Convergence Pharmaceuticals, Ltd., has now been acquired by Biogen.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Part 1 Inclusion Criteria:

  • Healthy male subjects aged between 18 and 65 yrs and female (of non-child bearing potential) subjects aged between 18 and 50 years.

Part 2 Inclusion Criteria:

  • right-handed healthy male subjects aged between 18 and 65 years.

Parts 1 & 2 Inclusion Criteria:

  • body weight >50 kg and Body Mass Index (BMI) within the range 19 - 29.9 kg/m2 inclusive.
  • No abnormality on relevant clinical examination.
  • No abnormality on relevant clinical chemistry or haematology examination at the pre-study medical examination.
  • A 12-lead ECG at the pre-study medical examination which is normal.
  • Non-smokers.
  • Signed and dated written informed consent prior to any study procedures being done.
  • The subject is able to understand and comply with protocol requirements, instructions and protocol-stated restrictions.

Parts 1&2 Exclusion Criteria:

  • exceeding weekly recommended alcohol intake.
  • An unwillingness of a male subject to use a condom/ spermicide in addition to having their female partner use another form of contraception.
  • A positive Hepatitis B surface antigen, Hepatitis C antibody, and Human Immunodeficiency Virus (HIV) antibody result at screening.
  • A positive urine drug test at screening or prior to each treatment period.
  • History of alcohol/drug abuse or dependence within 12 months of the study.
  • Urine cotinine levels indicative of smoking.
  • History or regular use of tobacco or nicotine containing products within 6 months prior to screening.
  • QTc interval > 450 ms.
  • Current or past history of symptomatic orthostatic hypotension. Sitting systolic blood pressure >139 or <90 mmHg and/or diastolic blood pressure >100 or <50 mmHg. Standing heart rate <45 bpm.
  • The subject has participated in a clinical trial and has received a drug or a new chemical entity within 30 days or 5 half-lives, or twice the duration of the biological effect of any drug (whichever is longer) prior to the first dose of current study medication.
  • Exposure to more than four new chemical entities within 12 months prior to the first dose of current study medication. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and sponsor the medication will not interfere with the study procedures or compromise subject safety.
  • Consumption of moderate/high tyramine containing food or drinks from 1 week prior to the first dose and until discharge, following the last dose.
  • History of hypersensitivity to lamotrigine.
  • History of sensitivity to any of the study medications, or components thereof.Or a history of drug, cosmetic or other allergy that, in the opinion of the physician, might interfere with the conduct of the study.
  • History of known or suspected seizures, including infantile febrile, unexplained significant and recent loss of consciousness or history of significant head trauma with loss of consciousness or a family history (first degree relative) of epilepsy or seizures (fits).
  • Where participation in study would result in donation of blood in excess of 500 mL within a 56 day period.

Part 2 Exclusion Criteria:

  • History of clinically relevant skin rashes and allergies.
  • Poorly-controlled migraine headaches.
  • Implanted metal devices including pacemakers.
  • Previous brain neurosurgery.
  • History of neurological disorders and stroke.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00488566


Locations
United Kingdom
GSK Investigational Site
Harrow, Middlesex, United Kingdom, HA13UJ
GSK Investigational Site
London, United Kingdom, SE1 1YR
Sponsors and Collaborators
Biogen
Investigators
Study Director: Biogen Medical Director Biogen
  More Information

Responsible Party: Biogen
ClinicalTrials.gov Identifier: NCT00488566     History of Changes
Other Study ID Numbers: SCB107718
First Submitted: June 18, 2007
First Posted: June 20, 2007
Last Update Posted: October 26, 2017
Last Verified: October 2017

Keywords provided by Biogen:
bipolar disorder,
single doses,
resting motor threshold
TMS,

Additional relevant MeSH terms:
Bipolar Disorder
Bipolar and Related Disorders
Mental Disorders
Lamotrigine
Anticonvulsants
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers